Pacific Shuanglin Bio-pharmacy Co Ltd

Pacific Shuanglin Bio-pharmacy maintains a conservative capital structure with a debt-to-equity ratio of 0.1 and a strong current ratio of 3.3, indicating ample short-term liquidity coverage. Despite holding total equity of 8.09 billion CNY against total liabilities of 1.38 billion CNY, the company reports negative operating cash flow of -216 million CNY and negative free cash flow of -27.7 million CNY, driven by capital expenditures of 333 million CNY. The risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting reliance on external financing or asset liquidation for long-term obligations despite strong current assets.

Profitability metrics show a return on equity of 8.81% and a return on assets of 7.53%, with a net income of 419 million CNY on revenue of 2.63 billion CNY. The company trades at a price-to-earnings ratio of 12.97 and an EV/EBITDA of 11.96, reflecting a moderate valuation relative to its earnings power. Without cohort median data for direct comparison, these returns appear stable but are constrained by the negative cash flow generation, which may limit internal reinvestment capacity.

Segment and geographic revenue concentration data is not provided in the available input, preventing a detailed analysis of revenue mix or regional exposure. The company’s activity is broadly classified as unclassified within the biotechnology sector, limiting specific insights into product line diversification or customer concentration.

Growth trajectory analysis is hindered by the absence of historical period data for revenue and net income trends. The latest financial snapshot shows a gross profit of 1.09 billion CNY, implying a gross margin of approximately 41.4%, but without multi-year data, the directionality of margin expansion or contraction cannot be determined.

Risk factors include medium liquidity risk and low dilution risk, with a key flag indicating negative net cash after debt subtraction. The company’s ESG profile shows a total score of 34.94 with a grade of C, characterized by a strong environment pillar (51.16) but a very low governance pillar score (6.95), which may signal internal control or transparency concerns. The low governance score is a notable risk factor for long-term sustainability and investor confidence.

Recent observations include an actual EPS of 0.44 CNY and an ESG controversies score of 100, indicating no major recent controversies. No specific filing, news, or transcript observations are provided to detail recent corporate actions or strategic shifts.

Operating and net margins are best-in-class, significantly exceeding the cohort medians of 7.5% and 5.3% respectively.

Analysts imply a 76.2% upside potential, with a consensus price target of 21.43 CNY versus the current 12.16 CNY.

The company maintains a conservative debt-to-equity ratio of 0.1, well below the cohort median of 0.4.

Revenue demonstrated a 7.5% compound annual growth rate over the four-year period ending in the latest fiscal year.

Cash conversion ratio of 0.45 is below the cohort median of 1.2, indicating weaker cash generation efficiency.

Long-term debt increased to 825.5 million CNY in the latest period, reflecting a rising leverage trajectory.

The company faces a medium level of liquidity risk, which could constrain operational flexibility during market stress.

Revenue ¥2.65B, +14,0% YoY; Operating income +26,4% YoY.

• ▍Revenue ¥2.65B, +14,0% YoY
• ▍Operating income +26,4% YoY
• ▍Net income +21,8% YoY
• ▍Free cash flow −68,3% YoY
• ▍Net margin 28.1%

Revenue ¥2.33B, −3,2% YoY; Operating income +5,2% YoY.

• ▍Revenue ¥2.33B, −3,2% YoY
• ▍Operating income +5,2% YoY
• ▍Net income +4,2% YoY
• ▍Free cash flow +8,3% YoY
• ▍Net margin 26.3%

Revenue ¥2.41B, +22,0% YoY; Operating income +43,5% YoY.

• ▍Revenue ¥2.41B, +22,0% YoY
• ▍Operating income +43,5% YoY
• ▍Net income +50,1% YoY
• ▍Free cash flow +69,6% YoY
• ▍Net margin 24.4%

Revenue ¥1.97B; Operating income ¥459.9M.

• ▍Revenue ¥1.97B
• ▍Operating income ¥459.9M
• ▍Net margin 19.8%